Novel Germline Mutation in BCAR1 in Two Siblings With Lung Cancer: a Possible Susceptibility Gene

doi:10.21203/rs.3.rs-73494/v1

Download PDF

Primary research

Novel Germline Mutation in BCAR1 in Two Siblings With Lung Cancer: a Possible Susceptibility Gene

https://doi.org/10.21203/rs.3.rs-73494/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Background: Lung cancer is the most prevalent malignancy worldwide. Most patients were sporadic and carried somatic mutations in hotspot genes. At present, accumulating researches had identified several germline mutations that predispose patients to lung cancer. In this report, two siblings were diagnosed as lung squamous cell carcinoma and lung adenocarcinoma, respectively.

Results: The two siblings shared similar features of a germline insertion of 11 bp (GCCCTGGCATT) in BCAR1 producing a frameshift at codon 314 which is located at the substrate domain. The BCAR1 was previously demonstrated to be associated with lung cancer. The variant detected in this report would impair the regulation and functions of BRCA1 in some extent, thus may promote lung cancer tumorigenesis. Our findings suggest that BCAR1 is a possible susceptibility gene for lung cancer, and its functional analyses in lung cancer need further investigation.

Conclusions: In this study, we first reported a novel causative mechanism of Lung cancer: an insertion of 11 bp in BCAR1 gene, which can be helpful in the genetic diagnosis of this disease.

Epigenetics & Genomics

Lung cancer

Germline mutation

BCAR1

Susceptibility gene

At present, lung cancer still ranks top one in cancer incidence and mortality[1], in which, non-small cell lung cancer is the predominant histologic type, mainly including adenocarcinoma and squamous cell carcinoma. The primary non-inherited risk factor for lung cancer is smoking, however, approximately 25% of lung cancer cases worldwide are not attributable to tobacco use[2]. Multiple risk factors, including environment, hormone and genetic predisposition, have been associated with the pathogenesis of lung cancer in never smokers. Among these factors, familial lung cancer had been reported[3], and persons with family history of lung cancer had a double-risk of developing the disease[4, 5]. Although familial forms of lung cancer is rarely described, several susceptibility genes have been identified, such as EGFR[3, 6], HER2[7], BAP1[8], and BRCA2[9], among which EGFR germline mutations were the most reported. In the current report, we presented two siblings with lung cancer harboring germline mutation in breast cancer anti-estrogen resistance protein 1 (BCAR1). BCAR1, encoding a scaffold protein, has been shown to be overexpressed in lung cancer and linked to adverse features in lung cancer[10-12]. Therefore, we suspected that BCAR1 germline mutation potentially predisposes patients to lung cancer.

Subjects

Peripheral blood samples were obtained from the proband and his family after informed consent was signed respectively. Experiment on human subjects was approved by Institutional Review Board of Huazhong University of Science and Technology, Wuhan, China. The two affected siblings’ brain MRI results were evaluated by two pediatric neuroradiologists.

Whole-exome sequencing

The DNA was isolated from the FFPE and blood samples using the DNeasy Blood and Tissue Kit (69504, QIAGEN, Venlo, Netherlands) according to the manufacturer’s instructions. DNA quantity was assessed by Agilent’s Bioanalyzer (USA). The targeted capture pulldown and exon-wide libraries from genomic DNA were generated through the TruePrep DNA Library Prep Kit V2 for Illumina (#TD501, Vazyme, Nanjing, China). The sequences of captured libraries were performed as pair-end reads on sequences on the Illumina HiSeq 2500 platform. Functional annotation was performed through ANNOVAR and data were filtered by public database, such as ExAC, 1000 Genomes Project, and HGMD.

Sanger sequencing

BCAR1, PRKRA and FAM20C for Sanger sequencing were selected based on evidence for association with 16 family samples. Multiple sequencing reactions were loaded onto multiwell plates, which were injected into capillaries for electrophoresis on the instrument. Fluorescent-labeled modified (dideoxy) nucleotides that terminate the formation of a new DNA strand as they encounter their complementary nucleotides in the target sequence. This results in DNA strands of variable length, which are separated on a gel by electrophoresis and reflect the sequence being analyzed. Each capillary is separately calibrated for the dyes used in the sequencing reactions so that the software can perform the multi-component analysis to identify each of the dye-labeled fragments. These sequencing reactions are then analyzed using special software.

Patient 1

Patient 1, a 68-year-old male, sought medical consultation for a one-week history of cough and hemoptysis without any inducing factors, and was diagnosed with space-occupying lesions of the left upper lung in a local hospital. Then he transferred to our department in May, 2018 for further management. The chest CT and PET-CT confirmed a 6.4×5.2 cm mass in the left upper lung (Figure 1A), and multiple nodules were also found. CT-guided lung biopsy revealed a non-small cell lung cancer with histological type of squamous cell (Figure 1B). The patient was diagnosed with stage IIIc lung squamous cell carcinoma (cT4N3M0) based on clinical-pathologic-radiographic correlation. Panel detection of cancer driver genes did not reveal any common alterations related with lung cancer. Then he received two cycle of chemotherapy using albumin paclitaxel and nedaplatin on May 30, 2018 and June 22, 2018, followed by radiotherapy (IMRT, PTV 60Gy/30F) on July 12, 2018. CT revealed that the tumor had shrunk (Figure 1C). However, the patient was readmitted for cough, chest distress and asthma in January, 2019. The repeated CT scan revealed tumor recurrence (Figure 1D). Subsequent treatment was not administrated because of the patient’s willingness, and he died on July, 2019.

Patient 2

Patient 2, a 51-year-old female, is the younger sister of patient 1. She complained of intermittent coughing for 1 month and sough medical consultation at a local hospital. Auxiliary examination revealed the presence of nodule in the right parahilar region, as well as the increased number and enlarged size of mediastinal lymph nodes. She transferred to our department in June, 2018. Subsequent PET-CT and enhanced CT showed a 2.7×2.2 cm mass in the right lower lung (Figure 2A). Multiple enlarged lymph nodes were also presented in the right parahilar region and mediastinum. CT-guided lung biopsy was performed on June 12, 2018. Pathological examination indicated lung adenocarcinoma (Figure 2B) with pleural metastasis, clinical stage was IVA (cT4N3M1a). The immunohistochemical (IHC) staining showed tumor cells with positivity for ALK. Similar with her brother, no common alterations related with lung cancer were identified by panel detection. Considering the positive ALK staining by IHC, the patient received one cycle of chemotherapy (Pemetrexeddisodium 800 mg dl + Carboplatin 0.5g dl) on June 17, 2018, then started treatment with crizotinib. Follow-up CT scan demonstrated partial response with the indication of tumor shrinkage (Figure 2C). On August 28, 2019, lung lesions were stable, however, brain MRI revealed potential metastasis (Figure 2D), and the patient is under treatment with alectinib at present.

Follow-up and outcomes

Two siblings were diagnosed with lung cancer, leading to the request of an evaluation of possible hereditary predisposition. Whole-exome sequencing was performed, and two shared deleterious germline mutations (BCAR1 and FAM20C) were identified. Of these, BCAR1 was considered as the best candidate, because germline mutation in FAM20C was also found in spouses of their relatives, and because BCAR1 have previously been associated with lung cancer. Both patients harbored a germline insertion of 11 bp (5’-GCCCTGGCATT-3’) producing a frameshift at codon 314 (Figure 3 and Figure 4A). The BCAR1 variant detected in this report could not be found in the ExAC database, indicating it as a novel variant. Among the sixteen family members tested, three were found to carry the BCAR1 variant (Figure 4B). To date, the three mutation carriers did not reveal any features of lung cancer.

Lung cancer remains the most prevalent malignancy worldwide. In the past decades, numerous somatic mutations have been identified in lung cancer tissues and further established an oncogene-centric molecular classification paradigm in this disease. In contrast, limited germline mutations have been identified. Here, we encountered a family in which two siblings developed lung cancer, leading to the evaluation of possible hereditary predisposition. Using whole-exome sequencing, two shared germline mutation in BCAR1 and FAM20C were identified. Germline testing was further extended to their family members. Eight family members and two spouses were found to carried FAM20C variant, and BCAR1 variant was identified in three family members, indicating BCAR1 variant as the potential candidate. In theory, the allele frequency of BCAR1 variant should be approximately either 50% or 100% (heterozygote or homozygote), however, the allele frequency of both patients revealed by whole-exome sequencing were less than 1/3. This result was caused by the low detection rate of inserted mutation. Therefore, the verification of sanger sequencing was further performed, and both patients were identified as heterozygote.

BCAR1 encodes p130cas protein which possesses an amino-terminal Src-homology 3 domain, a substrate binding domain, proline-rich and serine-rich regions, and a bipartite Src-binding domain in carboxy-terminal sequence[10, 13]. p130Cas itself has no intrinsic enzymatic or transcriptional activity, but they could control signaling events via phosphorylation and dephosphorylation and their association with effectors proteins in multimolecular complexes. Tyrosine phosphorylation is the major post-translational modification of p130Cas, mainly occurring in the substrate binding domain, which help to open binding sites for a variety of effector proteins[11]. p130Cas has been demonstrated in many studies to play a vital role in cell migration[14, 15], apoptosis[16, 17] and cell transformation[18]. p130Cas is also reported to be involved in the development and progression of several human cancers, including breast cancer[19, 20], prostate cancer[21, 22], as well as lung cancer[23]. In lung cancer, BCAR1 was usually overexpressed, and increased BCAR1 predicts poorer prognosis in non-small lung cancer[23, 24]. In this report, the detected BCAR1 variant occurred an 11 bp insertion at codon 314 which locates at the substrate binding domain, indicating that its association with effectors proteins would be impaired in some extent, thus leading to a wide-range downstream consequence. This influence cannot be underestimated, and may predispose patients to lung cancer. Therefore, BCAR1 is a possible susceptibility gene for lung cancer. Although the biological function of BCAR1 in lung cancer remains unclear, we believed that BCAR1 plays an important role in the development and progression of lung cancer. It is worth noting that the two siblings developed two different histologic type of lung cancer, revealing that BCAR1 may undergo different mechanisms to induced different histologic type of lung cancer. To further prove our hypothesis, investigation concerning the biological function of BCAR1 in lung cancer is urgent and necessary. In addition, there are another three carriers in good health condition, and a long-term follow-up is of great necessity.

Above all, our report revealed a possible susceptibility gene, BCAR1, and further investigation of biological function of BCAR1 in lung cancer is need. These findings may help to conclude and reveal specific variation types in BCAR1 , which is benefit for the diagnosis and then for the future precision treatment of Lung Cancer.

Acknowledgements

The authors thank Shanghai Tongshu Biotechnology Co., Ltd. for technical support and the patient and his family for their interest and cooperation.

Authors’ contributions

Kuikui Zhu designed the study experiments. Yingchao Zhao collected the data

and conducted the clinical evaluations. Lu Wu, Sijia Zhang, Yan Zong and Zhenyu Li performed whole-exome sequencing and sanger sequencing. Qianwen Li and Fang Cheng wrote the article. Rui Meng supervised the study experiments. All authors revised and approved the article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Consent for publication

Publication of data was informed consent to all individuals involved in this study.

Competing interests

The authors declare no conflict of interests.

Author details

Cancer Center, Union Hospital, Tongji Medical College，Huazhong University of Science and Technology. No.156 Wujiadun, Jianghan District, Wuhan city，China

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers--a different disease. Nat Rev Cancer. 2007;7(10):778-90.
Gazdar A, Robinson L, Oliver D, Xing C, Travis WD, Soh J, et al. Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. J Thorac Oncol. 2014;9(4):456-63.
Jonsson S, Thorsteinsdottir U, Gudbjartsson DF, Jonsson HH, Kristjansson K, Arnason S, et al. Familial risk of lung carcinoma in the Icelandic population. JAMA. 2004;292(24):2977-83.
Coté ML, Liu M, Bonassi S, Neri M, Schwartz AG, Christiani DC, et al. Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. Eur J Cancer. 2012;48(13):1957-68.
Yu HA, Arcila ME, Harlan Fleischut M, Stadler Z, Ladanyi M, Berger MF, et al. Germline EGFR T790M mutation found in multiple members of a familial cohort. J Thorac Oncol. 2014;9(4):554-8.
Yamamoto H, Higasa K, Sakaguchi M, Shien K, Soh J, Ichimura K, et al. Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Cancer Inst. 2014;106(1):djt338.
Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48(12):856-9.
Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet. 2014;46(7):736-41.
Barrett A, Pellet-Many C, Zachary IC, Evans IM, Frankel P. p130Cas: a key signalling node in health and disease. Cell Signal. 2013;25(4):766-77.
Defilippi P, Di Stefano P, Cabodi S. p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol. 2006;16(5):257-63.
Camacho Leal Mdel P, Sciortino M, Tornillo G, Colombo S, Defilippi P, Cabodi S. p130Cas/BCAR1 scaffold protein in tissue homeostasis and pathogenesis. Gene. 2015;562(1):1-7.
Chodniewicz D, Klemke RL. Regulation of integrin-mediated cellular responses through assembly of a CAS/Crk scaffold. Biochim Biophys Acta. 2004;1692(2-3):63-76.
Brábek J, Constancio SS, Siesser PF, Shin NY, Pozzi A, Hanks SK. Crk-associated substrate tyrosine phosphorylation sites are critical for invasion and metastasis of SRC-transformed cells. Mol Cancer Res. 2005;3(6):307-15.
Sanders MA, Basson MD. p130cas but not paxillin is essential for Caco-2 intestinal epithelial cell spreading and migration on collagen IV. J Biol Chem. 2005;280(25):23516-22.
Wei L, Yang Y, Zhang X, Yu Q. Cleavage of p130Cas in anoikis. J Cell Biochem. 2004;91(2):325-35.
Kim W, Kook S, Kim DJ, Teodorof C, Song WK. The 31-kDa caspase-generated cleavage product of p130cas functions as a transcriptional repressor of E2A in apoptotic cells. J Biol Chem. 2004;279(9):8333-42.
Ambrogio C, Voena C, Manazza AD, Piva R, Riera L, Barberis L, et al. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood. 2005;106(12):3907-16.
Cabodi S, Moro L, Baj G, Smeriglio M, Di Stefano P, Gippone S, et al. p130Cas interacts with estrogen receptor alpha and modulates non-genomic estrogen signaling in breast cancer cells. J Cell Sci. 2004;117(Pt 8):1603-11.
Makkinje A, Vanden Borre P, Near RI, Patel PS, Lerner A. Breast cancer anti-estrogen resistance 3 (BCAR3) protein augments binding of the c-Src SH3 domain to Crk-associated substrate (p130cas). J Biol Chem. 2012;287(33):27703-14.
Zhang XA, He B, Zhou B, Liu L. Requirement of the p130CAS-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration. J Biol Chem. 2003;278(29):27319-28.
Heumann A, Heinemann N, Hube-Magg C, Lang DS, Grupp K, Kluth M, et al. High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer. BMC Cancer. 2018;18(1):37.
Huang W, Deng B, Wang RW, Tan QY, He Y, Jiang YG, et al. BCAR1 protein plays important roles in carcinogenesis and predicts poor prognosis in non-small-cell lung cancer. PLoS One. 2012;7(4):e36124.
Deng B, Sun Z, Jason W, Yang P. Increased BCAR1 predicts poor outcomes of non-small cell lung cancer in multiple-center patients. Ann Surg Oncol. 2013;20 Suppl 3:S701-8.

Download PDF

Version 1

posted

You are reading this latest preprint version

Novel Germline Mutation in BCAR1 in Two Siblings With Lung Cancer: a Possible Susceptibility Gene

Status:

Version 1

Abstract

Figures

Background

Methods

Case Presentations

Discussion

Conclusion

Declarations

References

Status:

Version 1